Return to Listing

1 result(s) for

PI Name Protocol # Title
Ronan Swords STUDY00018590 [WIRB - IAA] Gilteritinib Monotherapy or in Combination with Decitabine in Elderly Untreated FLT3 mutated Acute Myeloid Leukemia With High and Low Variant Allele Frequency (VAF) (Group 1) OR Gilteritinib in Combination with Decitabine and Venetoclax in Untreated FLT3 mutated Acute Myeloid Leukemia age ≥18 years or older With High and Low Variant Allele Frequency (VAF) (Group 2)
 

You may also qualify for Phase 1 Program trials.

 
For more information:
Email: trials@ohsu.edu
Call: 503-494-1080